Lantern Pharma, Inc.

101 articles with Lantern Pharma, Inc.

• Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

  3/28/2023

  Lantern Pharma Inc. today announced the dosing of the first patient in the Phase 2 Harmonic™ clinical trial evaluating Lantern’s investigational new drug LP-300.

• Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

  3/21/2023

  Lantern Pharma Inc. announced that Lantern management and employees will be presenting at three upcoming events: Rare Disease Innovation & Partnership Summit in Philadelphia, PA on Wednesday, March 22 at 5:00 p.m. ET.

• Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

  3/20/2023

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.

• Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

  3/15/2023

  Lantern Pharma Inc. today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting. Details on the AACR presentation are provided below.

• Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET

  3/13/2023

  Lantern Pharma Inc. today announced that it will host its fourth quarter and fiscal year 2022 financial results webcast on Monday, March 20, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

• Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

  3/13/2023

  Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank.

• Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

  3/9/2023

  Lantern Pharma Inc. today announced new data for its product candidate LP-100 supporting the development of LP-100 in combination with the class of anticancer agents known as PARP inhibitors (PARPi).

• Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

  3/8/2023

  Lantern Pharma Inc. today announced that it will host a virtual key opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m. ET focusing on synthetic lethality, the unique and powerful mechanism of action behind Lantern’s drug candidates LP-184, LP-284, and LP-100.

• Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

  3/6/2023

  Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options.

• Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

  3/2/2023

  Lantern Pharma Inc. today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members.

• Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

  2/27/2023

  Collaborative efforts are aimed at using Lantern’s AI platform to accelerate and sharpen the drug development of TTC-352.

• Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

  2/15/2023

  Lantern Pharma Inc. (NASDAQ: LTRN) today announced expansions and updates to RADR®’s product roadmap, which will further enhance its oncology drug discovery capabilities.

• Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

  1/17/2023

  Lantern Pharma Inc. today announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern’s clinical development plans for its LP-184 program.

• FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

  1/5/2023

  Lantern Pharma Inc. (NASDAQ: LTRN) today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL).

• Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

  12/15/2022

  Lantern Pharma Inc. today announced it presented new positive preclinical data for its drug candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology Annual meeting.

• Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

  12/13/2022

  Lantern Pharma Inc. today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer.

• Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

  12/2/2022

  Lantern Pharma Inc, a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announces that Panna Sharma, CEO and President, will present at the RHK Capital Disruptive Growth Conference in New York City.

• Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

  11/22/2022

  Lantern Pharma Inc. today announced that it presented positive preclinical data on the efficacy of its drug candidate LP-184 for glioblastoma (GBM), used alone or in combination with the Food and Drug Administration (FDA) approved agent spironolactone, at the Society for Neuro-Oncology (SNO) annual meeting.

• Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

  11/7/2022

  Lantern Pharma Inc. announced operational highlights and financial results for the third quarter ended September 30, 2022.

• Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4

  11/2/2022

  Lantern Pharma Inc. today announced that Lantern management will be presenting at two upcoming investor conferences.